Home
Search
Search Results
Previously Searched
3091 results found
Expand All
Apply All
3091 results found

BIO Congratulates Alex Azar on Confirmation as Secretary of Health and Human Services
Press Release  •  January 24, 2018
BIO Congratulates Alex Azar on Confirmation asSecretary of Health and Human Services Washington, DC (January 24, 2018) – Biotechnology Innovation Organization (BIO) President and CEO Jim Greenwood issued the following statement regarding the confirmation of Alex Azar as United States Secretary of Health and Human Services (HHS):
Read More

BIO Releases First Report in a Series on the State of Innovation in Highly Prevalent Chronic Diseases
Press Release  •  January 18, 2018
First-of-its-kind report highlights the need to stimulate development efforts for depression therapeutics. Washington, DC (January 18, 2018) – Today, the Biotechnology Innovation Organization (BIO) released a new report, The State of Innovation in Highly Prevalent Chronic Diseases: Depression Therapeutics, the first in a series on the current funding and R&D land scape for drugs to treat highly prevalent, chronic diseases. 
Read More

BIO Statement on House Energy & Commerce Committee 340B Drug Pricing Program Review
Press Release  •  January 10, 2018
Washington, DC (January 10, 2018) – BIO President and CEO Jim Greenwood issued the following statement regarding the review of the 340B drug pricing program released by the House Energy & Commerce Committee today:
Read More

BIO Applauds Support for Innovation in Trump Administration Task Force Report
Press Release  •  January 9, 2018
“Biotechnology Sector is a Driver of the ‘Fourth Industrial Revolution’”Washington, D.C. (January 9, 2018) – The Biotechnology Innovation Organization (BIO) is applauding a new report from the Interagency Task Force on Agriculture and Rural Prosperity, which encourages growth and continued innovation in America’s biotechnology sector.
Read More

Insurance, Regulation and the Fight Against Opioid Addiction
Human Health, Opioids  •  Toolkit  •  January 5, 2018
Insurance coverage, reimbursement and regulatory challenges are preventing access to innovative treatments for pain and addiction. These barriers also are adversely impacting the investment needed to develop safer, next-generation therapies to treat pain and addiction that can help today to tame the opioid crisis.
Read More

BIO Statement on Retirement of Senator Orrin Hatch
Press Release  •  January 2, 2018
Washington, DC (January 2, 2018) – “BIO joins the nation – and the great state of Utah – in applauding Senator Hatch for his many years of service, and for proving time and time again to be a strong champion for biomedical innovation."
Read More

BIO Applauds House Passage of the Corporate Governance Reform and Transparency Act
Press Release  •  December 21, 2017
Washington, DC (December 21, 2017) – Today, the Biotechnology Innovation Organization (BIO) applauds the House of Representatives for passing H.R. 4015, the Corporate Governance Reform and Transparency Act.  This bipartisan bill, sponsored by Reps. Sean Duffy (R-WI) and Gregory Meeks (D-NY), was approved by a 238-182 vote.
Read More

BIO Applauds USTR for Standing Up for Ag Innovation and Sound Science
Press Release  •  December 14, 2017
U.S. Government and 16 like-minded WTO Members Call forImplementation of the Sanitary and Phytosanitary (SPS) AgreementWashington, D.C. (December 14, 2017) – The Biotechnology Innovation Organization (BIO) is applauding efforts by the United States Government and other World Trade Organization (WTO) members for committing to strengthen the implementation and application of Sanitary and Phytosanitary Measures (SPS Agreement).  
Read More

Dynamic Speaker Lineup Announced for BIO CEO & Investor Conference
Press Release  •  December 14, 2017
The Biotechnology Innovation Organization (BIO) today announces preliminary programing for the upcoming BIO CEO & Investor Conference to be held February 12-13, 2018 in New York. The program will include a diverse group of industry luminaries at the forefront of exciting science in such areas as gene therapy and new oncology treatments.
Read More

BIO Submits Comments Re: ICER Proposed Revisions to its Value Framework for Treatments for Ultra-Rare Diseases
Rare Diseases  •  Letters, Testimony & Comments  •  December 11, 2017
BIO appreciates the opportunity to comment on these proposed revisions. Patients living with rare diseases often experience significant unmet medical need due to the lack of knowledge about how these diseases are caused or inherited and their progression. That those suffering from rare diseases are predominately children raises issues around how society prioritizes and develops treatments for these conditions. We believe there are significant challenges in reconciling existing population-level value assessment methodologies with the varied healthcare contexts and deeply personal patient-level treatment decisions faced by patients afflicted with rare diseases, their families, and their clinicians. For a number of reasons, applying a patient-centric lens when considering the value of treatment is especially important when considering rare diseases.
Read More